# ResMed Inc. – Consensus ‘buy’ rating and 37.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/resmed-inc.consensus-buy-rating-and-37.4-upside-potential/4121129265
- Published: 2023-10-12T12:34:09+01:00
- Author: Charlotte Edwards

**ResMed Inc.** with ticker code (RMD) have now 8 analysts in total covering the
stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges
between 275 and 165 calculating the average target price we see $206.63. Given that
the stocks previous close was at $150.41 this would imply there is now a potential
upside of 37.4%. The 50 day MA is $159.16 and the 200 day moving average is $204.35.
The company has a market cap of 21.21B. The stock price for the company is currently
is currently 144.23 USD

 The potential market cap would be $29,143,428,116 based on the market consensus.

The company has a dividend yield of 2.05%. Other points of data to note are a P/
E ratio of 23.68, revenue per share of 28.77 and a 12.15% return on assets.

ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged
in the development, manufacturing, distribution and marketing of medical devices
and cloud-based software applications that diagnose, treat and manage respiratory
disorders, including sleep-disordered breathing, chronic obstructive pulmonary disease,
neuromuscular disease and other chronic diseases. It also offers software solutions
for a variety of out-of-hospital care providers. The Company has two segments: Sleep
and Respiratory Care and the Software-as-a-Service. Sleep apnea includes obstructive
sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based
digital health applications, along with its devices, are designed to provide connected
care to improve patient outcomes. The Company’s portfolio of products includes ventilation
devices, diagnostic products, mask systems, headgear and other accessories, dental
devices and cloud-based software informatics solutions.

Share on: